Global Antibody Production Market Analysis & Global Forecast to 2019 for the $2.5 Billion Market

May 19, 2015, 07:59 ET from Research and Markets

DUBLIN, May 19, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/47gwnj/antibody) has announced the addition of the "Antibody Production Market by Product, Type, Technology & by End-User - Analysis & Global Forecast to 2019" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


The global antibody production market is expected to reach $2.572 Billion in 2019 from $1.425 Billion in 2014, growing at a CAGR of 12.5%. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the fastest rate during the forecast period. 

Antibodies, also known as immunoglobulins, are specialized immune proteins produced when an antigen enters the body. Antibodies are produced by the immune system in response to the presence of foreign antigens or targets such as viruses and bacteria. Antibodies can be produced using hybridoma and hybridoma-free techniques. The major types of antibodies produced are monoclonal and polyclonal antibodies. 

The global antibody production market is segmented on the basis of products, types, technologies, end users, and regions. By product, this market is categorized into equipment and consumables. In 2014, the consumables segment accounted for the largest share of this market. This segment is expected to grow at the fastest rate during the forecast period (2014 to 2019). 

On the basis of type, this market is divided into monoclonal and polyclonal antibodies. In 2014, the monoclonal antibodies segment accounted for the largest share of the market. However, the polyclonal antibodies segment is expected to grow at the fastest rate during the forecast period. 

The globa market, by technology, is segmented into hybridoma and hybridoma-free technologies. In 2014, the hybridoma technology segment accounted for the largest share of the market. However, the hybridoma-free technology segment is expected to grow at the fastest rate during the forecast period. 

This market, by end user, is segmented into biotechnology and pharmaceutical companies, diagnostic laboratories, and research institutes. The biotechnology and pharmaceutical companies segment is the largest and fastest-growing segment of the antibody production market. 

The key factors that are expected to spur the growth of this market are increasing demand for monoclonal antibodies globally and rising R&D expenditure of pharmaceutical and biotechnology companies. Moreover, emerging markets of India and China, rising demand for protein therapeutics, and increasing risk of pandemics and infectious diseases are likely to increase the demand for equipment and consumables used in antibody production. However, high cost of primary antibodies is likely to restrain the growth of this market. 

Some of the major players in the global market include GE Healthcare (U.K.), Thermo Fisher Scientific, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), Merck Millipore (U.S.), Abcam plc (U.K.), Amgen (U.S.), Sanofi S.A. (France), Rockland Immunochemicals, Inc. (U.S.), and Roche Applied Science (Germany). 

For more information visit http://www.researchandmarkets.com/research/47gwnj/antibody


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets